NOTE
🌱 created from: mgc1l
nivofgfr2
- Design: Phase 2, single-arm, multi-center trial
- Number of patients: 23 patients enrolled
- Patients characteristics: HER2-negative with centrally confirmed expression of PD-L1 and FGFR2
- Agent: Nivolumab 360 mg with CapeOX (capecitabine and oxaliplatin)
- Treatment line: First-line
- Trial Acronym/NCTId Number: NIVOFGFR2, NCT05859477
| Parameter | Result |
|---|---|
| 1-year PFS rate | 30.4% |
| Median PFS | 6.2 months |
| ORR | 21.7% |
- Highlight of toxicity: Grade ≥3 treatment-related adverse events reported in 9 (39.1%) patients
- One-line summarize: Nivolumab in combination with chemotherapy shows modest efficacy and acceptable safety profile in patients with FGFR2-positive, PD-L1-positive metastatic GC.